ProQR Therapeutics N.V [PRQR] stock prices are up 6.09% to $3.66 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The PRQR shares have gain 4.87% over the last week, with a monthly amount glided 107.95%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
ProQR Therapeutics N.V [NASDAQ: PRQR] stock has seen the most recent analyst activity on October 29, 2024, when Raymond James upgraded its rating to a Strong Buy and also boosted its price target to $14 from $6. Previously, Chardan Capital Markets upgraded its rating to Buy on November 08, 2023, and kept the price target unchanged to $2. On March 30, 2023, upgrade upgraded it’s rating to Mkt Outperform and revised its price target to $5 on the stock. Cantor Fitzgerald upgraded its rating to a Overweight and increased its price target to $5 on December 22, 2022. Citigroup downgraded its rating to a Neutral and reduced its price target to $1.70 on February 14, 2022. Stifel downgraded its rating to Hold for this stock on February 11, 2022, and downed its price target to $3. In a note dated February 11, 2022, Raymond James downgraded an Mkt Perform rating on this stock.
The stock price of ProQR Therapeutics N.V [PRQR] has been fluctuating between $1.13 and $4.62 over the past year. Currently, Wall Street analysts expect the stock to reach $3.63 within the next 12 months. ProQR Therapeutics N.V [NASDAQ: PRQR] shares were valued at $3.66 at the most recent close of the market. An investor can expect a potential drop of -0.82% based on the average PRQR price forecast.
Analyzing the PRQR fundamentals
The ProQR Therapeutics N.V [NASDAQ:PRQR] reported sales of 16.64M for trailing twelve months, representing a surge of 417.56%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -1.85%, Pretax Profit Margin comes in at -1.39%, and Net Profit Margin reading is -1.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.55 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.42 points at the first support level, and at 3.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.85, and for the 2nd resistance point, it is at 4.04.
Ratios To Look Out For
It’s worth pointing out that ProQR Therapeutics N.V [NASDAQ:PRQR]’s Current Ratio is 2.73. On the other hand, the Quick Ratio is 2.73, and the Cash Ratio is 2.12. Considering the valuation of this stock, the price to sales ratio is 21.92, the price to book ratio is 8.49.
